#USA #Trailhead Biosystems #Beachwood #iPSC Technology #Hematopoietic Cells

Trailhead Biosystems Expands Product Portfolio with TrailBio® Hematopoietic Progenitor Cells

On August 5, 2025, Trailhead Biosystems, Inc., a biotechnology company known for its innovative human cell models derived from induced pluripotent stem cells (iPSC), announced the commercial launch of its new hematopoietic progenitor cells, TrailBio®. These cells are produced from a well-characterized iPSC line using the company’s proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, providing researchers with a consistent and scalable tool for hematopoietic research.

TrailBio® hematopoietic progenitor cells express essential hematopoietic markers, including CD34, CD43, and CD90. Functional characterization has confirmed their ability to form myeloid and erythroid colonies in colony-forming unit (CFU) assays. This demonstrates not only a capacity for differentiation into multiple hematopoietic lineages but also evidence of their hematopoietic commitment through transcriptomic profiling.

These progenitor cells are designed for various applications, such as modeling hematopoietic diseases, drug screening, and studying hematotoxicity. They offer a reliable human model system that eliminates donor variability, thereby supporting reproducible results across different experiments.

David Llewellyn, CEO of Trailhead Biosystems, expressed that these hematopoietic progenitor cells significantly enrich their product lineup by providing high-quality, human-relevant cellular models. The stability and multipotency of these cells enable scientists to push forward in both hematopoietic biology and therapeutic development.

Angelica Gomes Ueltschy, Chief Scientific Officer at Trailhead Biosystems, added that these cells offer a trustworthy combination of purity, potency, and versatility. With their strong expression of markers and multi-lineage differentiation capabilities, they are particularly suitable for modeling blood disorders and evaluating potential therapeutic candidates.

For detailed cell characterization data and additional information, interested parties can visit TrailBio.com.

About Trailhead Biosystems

Founded in 2015 as a spin-off from the Cleveland Clinic and Case Western Reserve University, Trailhead Biosystems, Inc. is pioneering a computer-based approach to regenerative medicine and drug discovery. Their innovation stems from the research of Dr. Jan Jensen, the founder and Chief Scientific and Technology Officer. Trailhead utilizes its patented HD-DoE® platform to create scalable, optimized human cells by integrating advanced mathematical models with high-performance robotic manufacturing. This cutting-edge system allows the company to develop high-quality, specialized human cells derived from iPSCs tailored for drug discovery and cell-based therapies. The TrailBio® hematopoietic progenitor cells join a growing portfolio of iPSC-derived human cell types aimed at bridging the gap between discovery and clinical translation.